Literature DB >> 31323136

Acute arthritis and arthralgia as an adverse drug reaction to dupilumab.

L E M de Wijs1, J D van der Waa1, P H P de Jong2, D J Hijnen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31323136     DOI： 10.1111/ced.14050

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  5 in total

1.  Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.

Authors:  Lorena Miss Ozuna; Tessa Ryan; Jillian C Bensko; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2022-02-03       Impact factor: 6.347

Review 2.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

3.  Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management.

Authors:  Ryan Jay; Jaimie Rodger; Matthew Zirwas
Journal:  JAAD Case Rep       Date:  2022-01-06

4.  Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis.

Authors:  Ecem Bostan; Duygu Gülseren; Zehra Özsoy; Fatma Bilge Ergen
Journal:  Arch Rheumatol       Date:  2021-06-24       Impact factor: 1.007

5.  Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.

Authors:  Joaquim Mullol; Tanya M Laidlaw; Claus Bachert; Leda P Mannent; G Walter Canonica; Joseph K Han; Jorge F Maspero; Cesar Picado; Nadia Daizadeh; Benjamin Ortiz; Yongtao Li; Marcella Ruddy; Elizabeth Laws; Nikhil Amin
Journal:  Allergy       Date:  2021-10-01       Impact factor: 14.710
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.